Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$6.30 USD
+0.24 (3.96%)
Updated May 31, 2024 04:00 PM ET
After-Market: $6.31 +0.01 (0.16%) 7:58 PM ET
4-Sell of 5 4
C Value A Growth F Momentum B VGM
Brokerage Reports
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 81 - 100 ( 1019 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
We Are Unsurprised by MD-7246''s Failure; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Decent LINZESS Traction Under Pandemic''s Shadow; Yet Headwinds Remain; Adjusting PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
2019 Financial Results Reported; Near-Term Growth Anemic; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Settlement Reached With Final Holdout; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Patent Litigation Settlement; Four Down, One to Go; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended November 15
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended November 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q19 Financials Reported; Moderately Better Revenue Growth; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology - Recent Drug Launch Weekly Retail Sales Tracker - Week Ended October 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D